Bridging gap in the treatment of Alzheimer’s disease via postbiotics: Current practices and future prospects

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102689 - 102689

Published: Feb. 1, 2025

Language: Английский

---

Postbiotics as Molecules Targeting Cellular Events of Aging Brain—The Role in Pathogenesis, Prophylaxis and Treatment of Neurodegenerative Diseases

Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2244 - 2244

Published: July 12, 2024

Aging is the most prominent risk factor for neurodegeneration occurrence. The common neurodegenerative diseases (NDs), Alzheimer’s (AD) and Parkinson’s (PD) diseases, are characterized by incidence of proteinopathy, abnormal activation glial cells, oxidative stress, neuroinflammation, impaired autophagy cellular senescence excessive patient’s age. Moreover, mitochondrial disfunction, epigenetic alterations neurogenesis inhibition, together with increased blood–brain barrier permeability gut dysbiosis, have been linked to ND pathogenesis. Since NDs still lack curative treatment, recent research has sought therapeutic options in restoring microbiota supplementing probiotic bacteria-derived metabolites beneficial action host—so called postbiotics. current review focuses on literature explaining mechanisms involved pathogenesis addressing impact that postbiotics as a whole mixture particular metabolites, such short-chain fatty acids (SCFAs), lactate, polyamines, polyphenols, tryptophan exopolysaccharides bacterial extracellular vesicles, ageing-associated processes underlying also discusses issue implementing into prophylaxis therapy, depicting them compounds senescence-triggered dysfunctions worth translating from bench pharmaceutical market response “silver consumers” demands.

Language: Английский

---

Gut Microbiota, Bacterial Translocation, and Stroke: Current Knowledge and Future Directions

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2781 - 2781

Published: Dec. 6, 2024

Stroke is one of the most devastating pathologies in terms mortality, cause dementia, major adult disability, and socioeconomic burden worldwide. Despite its severity, treatment options remain limited, with no pharmacological therapies available for hemorrhagic stroke (HS) only fibrinolytic therapy or mechanical thrombectomy ischemic (IS). In pathophysiology stroke, after acute phase, many patients develop systemic immunosuppression, which, combined neurological dysfunction hospital management, leads to onset stroke-associated infections (SAIs). These worsen prognosis increase mortality. Recent evidence, particularly from experimental studies, has highlighted alterations microbiota–gut–brain axis (MGBA) following which ultimately disrupts gut flora increases intestinal permeability. changes can result bacterial translocation (BT) sterile organs, further contributing development SAIs. Given novelty significance these processes, especially role BT SAIs, this review summarizes latest advances understanding phenomena discusses potential therapeutic strategies mitigate them, reducing post-stroke complications improving outcomes.

Language: Английский

---

Gut Microbiome Variation in Patients with Early-Stage Mild-to-Moderate Intracerebral Hemorrhage: A Pilot Study Exploring Therapeutic Targets

Journal of Stroke and Cerebrovascular Diseases, Journal Year: 2024, Volume and Issue: 33(11), P. 108001 - 108001

Published: Sept. 10, 2024

Language: Английский

---